NEW YORK, Feb. 26 - Paradigm Genetics and VDDI Pharmaceuticals will research and develop novel antibiotics for certain bacteria that may be used as bioterror agents, the companies said on Tuesday.

Terms of the deal call for Paradigm to supply its MetaVantage platform. VDDI, meanwhile, will provide samples of a new class of antimicrobials recently discovered at the University of Alabama.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.